Oppenheimer Upgrades Moderna to Outperform, Announces $142 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh has upgraded Moderna (NASDAQ:MRNA) from Perform to Outperform and set a new price target of $142.

January 02, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's stock rating has been upgraded by Oppenheimer from Perform to Outperform, with a new price target of $142, suggesting a positive outlook.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest a better-than-expected future performance. The new price target of $142 by Oppenheimer indicates a significant upside potential for Moderna's stock, which is likely to be taken positively by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100